MALARIA ELIMINATION THROUGH ASYMPTOMATIC DIAGNOSIS 

THE PROBLEM

THE CASE FOR MALARIA ERADICATION
Damaged Public Health

Malaria is an infectious disease of the most vulnerable that affected

229 million people

and killed

409'000 people

67%

were children under the age of five

Impoverished Community

Malaria is among

the reasons for

lost economic growth

, particularly for low-income countries.

An example:

12

billion

the annual lost GDP caused by malaria in Africa

also the number for

the global annual direct costs of malaria,

including illness, treatment and premature deaths

THE CASE FOR ASYMPTOMATIC DIAGNOSIS

60

of malaria cases are asymptomatic.

20-50

of onward tranmission are accounted by asymptomatic cases, which makes malaria elimination in a region near impossible.

However,

current malaria diagnostic

technologies on the market

(

Malaria Rapid Diagnostic Tests (RDTs)

microscopy

)

are not designed to detect asymptomatic carriers.

Therefore,

the World Health Organization currently cannot provide policy and guidance on asymptomatic screening in their global strategy on malaria eradication, leaving the global market for asymptomatic malaria diagnostics unaddressed.

 
Image by João Rafael

Asymptomatic patients are one of our main concerns right now because a good proportion of the latest outbreaks we've seen are initiated by asymptomatic patients. The rest is imported cases, but if at least we could better diagnose them it will be a game changer.

Manuel Garcia, M.D.

GAD Associate CHAI (Clinton Health Access Initiative) / Malaria Access Program Mesoamerica

 

HOW OUR CAMPAIGN WORKS

01

INCENTIVIZE & EDUCATE

Raise awareness of the importance of malaria asymptomatic screening and improve general health literacy within the local community in regard to malaria elimination through our collaboration with local health organizations.

Technical training for local health practitioners on the use of our novel malaria diagnostic toolkit.

02

SCREENING
USING VIVAKIT

All asymptomatic diagnoses will be done using VivaKit - Hemolytics' novel malaria diagnostic toolkit - with a dual approach: active case detection (ACD) and reactive case detection (RACD).

03

TREATMENT & DATA COLLECTION

Detected asymptomatic carriers of the malaria parasites will be treated accordingly.

Data will be collected to evaluate the impact of asymptomatic screening in eliminating malaria.

MEET HEMOLYTICS

OUR STORY

Hemolytics is a medtech start-up based in the bilingual city of Fribourg, Switzerland. Originally a research project at the Adolphe Merkle Institute at the University of Fribourg, Hemolytics has grown into an impact-driven spin-off with a pre-founding team that is currently planning for Hemolytics' foundation at the end of summer 2021. The company's mission is to bring Hemolytics' life-saving technology to as many underserved communities as possible.

team icon.png
OUR VISION

We aim to demonstrate the importance of asymptomatic screening in the arsenal of tools to fight malaria, which will help the World Health Organization to officially endorse asymptomatic screening in their global strategy or malaria eradication. This will allow the creation of supporting policy and guidance for us as well as other innovators that share the mutual goal of removing this ancient disease from our world once and for all.

OUR TEAM

We are a multidisciplinary team of five changemakers who are inspired to create a lasting social impact through knowledge-based innovation and entrepreneurship (click on the images for more details).

To play, press and hold the enter key. To stop, release the enter key.

Behind the pre-founding team is our board of advisors, who have been guiding us with their scientific insight, industry experience, and more importantly, a strong belief in Hemolytics and its mission (click on the images for more details).

To play, press and hold the enter key. To stop, release the enter key.

pngkey.com-cd-icon-png-3297696.png
OUR MILESTONES (HIGHLIGHTS)

2016

19th May: Patent application

calendar%20icon_edited.png
OUR TIMELINE

2021

  • Seed round funding

  • Incorporate Hemolytics SA

 

OUR

SUPPORTERS

AMI.jpg
1200px-Universität_Freiburg_(Schweiz)_lo
SNSF.png
SERI.jpg
Novarrtis foundation.png
grs_logo_CMYK.jpg
SEIF-innovation-invest-logo-web-black.pn
 
 

HELP US END MALARIA!

We'll get right to the point: We're asking you to help support Hemolytics' asymptomatic screening campaigns.
Your support can be in any forms: financial sponsorship to run a campaign, a supply of antimalarial treatments for an entire campaign, connections to local community leaders and health practitioners where our campaigns are needed, and more.
If you believe that you can support us, please let us know by filling in the form.

Thanks for submitting!